VACCINATION. .1 ML SUBCUTANEOUSLY OR SUBMUCOSAL OR INTRADERMAL
TREATMENT OF CHOICE & PROPHYLAXIS FOR CARCINOMA IN SITU & PROPHYLAXIS OF PRIMARY OR RECURRENT STAGE TA AND/OR T1 PAPILLARY TUMORS FOLLOWING TRANSURETHRAL RESECTION. NOT RECOMMENDED FOR STAGE TAG1 PAPILLARY TUMORS, UNLESS THEY ARE JUDGED TO BE AT HIGH RISK OF TUMOR RECURRENCE : TREATMENT IS NOT STARTED UNTIL 10 TO 14 DAYS AFTER BLADDER BIOPSY OR TRANSURETHRAL RESECTION. A NUMBER OF REGIMENS HAVE BEEN TRIED; TYPICALLY, BCG IS INSTILLED INTO THE BLADDER ONCE WEEKLY FOR 6 WEEKS, FOLLOWED AFTER A 6-WEEK GAP BY FURTHER INSTILLATIONS ONCE WEEKLY FOR 1 TO 3 WEEKS. MAINTENANCE THERAPY IS RECOMMENDED AND CONSISTS OF INSTILLATIONS EVERY 1 TO 3 WEEKS AT 6 MONTHS AFTER INITIATION OF TREATMENT AND THEN EVERY 6 MONTHS THEREAFTER UP TO 36 MONTHS.
URINE VOIDED FOR 6 HOURS AFTER INSTILLATION OF BCG VACCINES SHOULD BE DISINFECTED WITH SODIUM HYPOCHLORITE SOLUTION.